Table 1.
Subject Demographics. Demographics and baseline biomarker levels for all enrolled subjects and subjects included in biomarker analysis.
| Total (N = 103) |
Available (N = 88) |
Samples unavailable (N = 15) |
|
|---|---|---|---|
| Age | |||
| Mean (SD) | 63 (± 9.1) | 64 (± 8.9) | 58 (± 8.8) |
| Sex | |||
| Female | 36 (± 35.0%) | 31 (35.2%) | 5 (33.3%) |
| Male | 67 (± 65.0%) | 57 (± 64.8%) | 10 (± 66.7%) |
| Race | |||
| Asian | 1 (1.0%) | 1 (1.1%) | 0 (0%) |
| Black or African American | 2 (1.9%) | 2 (2.3%) | 0 (0%) |
| Other race | 6 (5%) | 6 (6.8%) | 0 (0%) |
| White | 94 (91.3%) | 79 (89.8%) | 15 (100%) |
| Treatment | |||
| Mab + Pac + Car + Bev | 52 (50.5%) | 43 (48.9%) | 9 (60.0%) |
| Pac + Car + Bev | 51 (49.5%) | 45 (51.1%) | 6 (40.0%) |
| Baseline NfL (pg/mL) | |||
| Mean (SD) | 27 (± 30) | 27 (± 30) | NA |
| Missing | 15 (14.6%) | 0 (0%) | 15 (14.6%) |
| Baseline GFAP (pg/mL) | |||
| Mean (SD) | 100 (± 56) | 100 (± 56) | NA |
| Missing | 48 (46.6%) | 33 (37.5) | 15 (14.6%) |
| Treatment duration (days) | |||
| Mean (SD) | 180 (± 130) | 200 (± 130) | 75 (± 88) |
MAb: Experimental monoclonal antibody; Pac: Paclitaxel, Car: Carboplatin, Bev: Bevacizumab, NA: Not applicable.